A practical reference on albumin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
=== ColdFusion 4.5 === Version 4.5, released in Nov 1999, expanded the ability to access external system resources, including COM and CORBA, and added initial support for Java integration (including EJB's, Pojo's, servlets, and Java CFX's). IT also added the getmetricdata function (to access performance information), additional performance information in page debugging output, enhanced string conversion functions, and optional whitespace removal.
Indirect discrimination is often structural, and this is seen in the gender pay gap of 21.7% across the Australian workforce, meaning women employees earn on average 78.3 cents compared to each $1 for male employees, according to the annual employer census. The main reasons for the gender pay gap are sex discrimination in child care and parental leave laws based on "persistent cultural norms that see women as more likely to undertake primary carer duties for children and family", "outright gender-based discrimination at work", "patterns of workforce engagement" and occupational segregation. Under the Fair Work Act 2009 section 302, employees, unions and the Sex Discrimination Commissioner can make an equal pay claim. The first post-2009 cases were brought by unions for social and community service workers, supported by the government. The Fair Work Commission interprets the appropriate comparator narrowly. Before 2009, the Librarians case, librarians were awarded a pay increase since the skill and education levels were comparable to better paid male-dominated industries. Structural discrimination also underlies much of the race pay gap in Australia. The first time Indigenous employees became legally entitled to equal pay with white workers, in cattle and farming jobs, was through a decision in 1966. The exclusion in the Conciliation and Arbitration Act 1904 section 4 for "persons engaged in domestic service" meant that many Indigenous women and girls employed as domestic staff were excluded.
In contrast nitrooxylation of 1 with nitric acid gives the apical nitrate 4 as an intermediate which is hydrolysed to the apical alcohol 5 due to the higher steric demand of the active electrophilic NO−2HNO+3 species. This alcohol can react with thionyl bromide to the bromide 6 and in a series of steps (not shown) to the corresponding thiol. Pentamantane can also react with tetrabromomethane and tetra-n-butylammonium bromide (TBABr) in a free radical reaction to the bromide but without selectivity.
Sources: en.wikipedia.org
=== David Healy === David Maurice Healy is played by Johnny Galecki. David is Mark Healy's younger brother. He first appeared in "The Bowling Show" (episode 4.14). Whereas Mark was initially a rebellious delinquent, David is friendly and respectful to the Conners. He is shy, polite, thoughtful, sensitive, soft-spoken, artistic, and intelligent. Much of his passive behavior results from his difficult home life and his mother's abusive behavior. He is romantically involved with Darlene, becoming the submissive partner. They also collaborate artistically, with David illustrating graphic novels that Darlene writes. His sweet manner endears him to the Conners, who eventually consider him as part of the family and jokingly refer to him as being more welcome than Darlene. He moves in with the Conners after Roseanne, herself a victim of child abuse, witnesses how abusive David's mother is. David and Darlene break up three times throughout the series, each for a successively longer period of time, but always reunite. After Darlene becomes pregnant, she and David married. In the series finale, Roseanne reveals in her writing that David had actually been dating Becky in "real life", and that Roseanne simply wrote his relationship as being with Darlene because she felt it made more sense. The series finale is retconned for season 10, where it is revealed that David and Darlene have been separated for some years and David has been away, traveling and doing volunteer work abroad, leaving Darlene to raise their two children, Harris and Mark, as a single mother.
== Selected recent publications == Biggar, K.K., and Storey, K.B. Functional impact of non-coding RNA regulation in extreme stress adaptation. J. Mol. Cell. Biol. In Press. doi.org/10.1093/jmcb/mjx053 Biggar, K.K., Wang Z. and Li, S. SnapShot: Lysine methylation beyond histones. Mol. Cell 68(5):1016–1016.e1. Invited submission Singal, S.S., Nygard, K.*, Biggar, K.K.*, Shehab, M.A., S.S.C. Li, Jansson, T. and Gupta, M.B. Interaction between IGFBP-1, protein kinase CSNK-2 and mTOR in HepG2 cells as demonstrated by dual immunofluorescence and in situ PLA. Am. J. Pathol. In press, doi.org/10.1016/j.ajpath.2017.09.009 Biggar, K.K., Dawson, N.J. and Storey, K.B. Native protein denaturation using urea. Biotechniques 62(1): xiii (epub) Shehab, M.A., Biggar, K.K., Singal, S.S., Nygard, K., Li, S.S.C., Jansson, T. and Gupta, M.B. Exposure of decidualized HESC to low oxygen tension and leucine deprivation results in increased IGFBP-1 phosphorylation and reduced IGF-I bioactivity. Mol. Cell. Endo. 452:1-14 Wu, Z., Connolly, J. and Biggar, K.K. Beyond histones: The expanding roles of lysine methylation. FEBS J. 284(17): 2732-2744 Biggar, K.K. and Storey, K.B. Exploration of low temperature microRNA function in an anoxia tolerant vertebrate ectotherm, the red eared slider turtle (Trachemys scripta elegans). J. Thermal Biol. In Press Wu, C.W., Biggar, K.K., Luu, B.E., Szereszewski, K.E. and Storey, K.B. Analysis of microRNA expression during the torpor-arousal cycle of a mammalian hibernator, the 13-lined ground squirrel. Physiol. Genomics DOI: 10.1152/physiolgenomics.00005.2016
Tramadol and tapentadol carry additional risks associated with their dual effects as SNRIs and can cause serotonin syndrome and seizures. Despite these risks, there is evidence to suggest that these drugs have a lower risk of respiratory depression compared to morphine.
== Biological activity == Amines are ubiquitous in biology. The breakdown of amino acids releases amines, famously in the case of decaying fish which smell of trimethylamine. Many neurotransmitters are amines, including epinephrine, norepinephrine, dopamine, serotonin, and histamine. Protonated amino groups (–NH+3) are the most common positively charged moieties in proteins, specifically in the amino acid lysine. The anionic polymer DNA is typically bound to various amine-rich proteins. Additionally, the terminal charged primary ammonium on lysine forms salt bridges with carboxylate groups of other amino acids in polypeptides, which is one of the primary influences on the three-dimensional structures of proteins.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.